1. Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients
   YAN HUANG et al, 2015 CrossRef
2. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
   Cristina Pérez-Ramírez et al, 2018, Pharmacogenomics J CrossRef
3. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
   Cristina Pérez-Ramírez et al, 2016, Pharmacological Research CrossRef
4. Çocukluk Çağı Akut Lenfoblastik Lösemili Hastalarda RFC G80A Polimorfizmi ve MTHFR Polimorfizmleri ile İlişkilendirilmesi
   Dilara Fatma Akın et al, 2018 CrossRef
5. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy
   Jose JG Marin et al, 2014, Acta Pharmacol Sin CrossRef
6. Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations
   A Corrigan et al, 2014, Pharmacogenomics J CrossRef
7. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis
   Yu Liu et al, 2013, Cancer Chemother Pharmacol CrossRef
8. Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
   Ali A. Bukhari et al, 2013, Lung Cancer International CrossRef
9. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
   Aurea Lima et al, 2014, Mol Biol Rep CrossRef
10. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
    Paweł Krawczyk et al, 2014, J Cancer Res Clin Oncol CrossRef
11. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
    Xiaoying Li et al, 2014, Tumor Biol. CrossRef
12. Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
    Xiaoqing Zhang et al, 2019, Front. Pharmacol. CrossRef
13. On the pharmacogenetics of non-small cell lung cancer treatment
    Mariacarmela Santarpia et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
14. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine
    Ji-Ye Yin et al, 2016, Pharmacogenomics CrossRef
15. Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.
    Stephen J Bagley et al, 0 CrossRef
16. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
    Cristina Pérez-Ramírez et al, 2017, Mutation Research/Reviews in Mutation Research CrossRef
17. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis
    Li-Ming Tan et al, 2017, Sci Rep CrossRef
18. Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks
    Mehrab Ghanat Bari et al, 2017, Sci Rep CrossRef
19. Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
    Ryosuke Tanino et al, 2018, Oncotarget CrossRef
20. Potential insights from population kinetic assessment of progression-free survival curves
    David J. Stewart et al, 2020, Critical Reviews in Oncology/Hematology CrossRef
21. Correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC: A meta-analysis
    Feng Han et al, 2021 CrossRef
22. MTHFR polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients
    Harleen Kaur Walia et al, 2021, Journal of Chemotherapy CrossRef
23. Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
    Che-Hsing Li et al, 2021, CMAR CrossRef
24. Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients
    Lei Cao et al, 2022, Current Oncology CrossRef
25. Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients.
    Yu Bai et al, 2021, J Chemother CrossRef
26. ANALYSIS OF THE TSER AND G > C VARIANTS IN THE TYMS GENE: A HIGH FREQUENCY OF LOW EXPRESSION GENOTYPES PREDICTED IN THE MEXICAN POPULATION
    Favela-Mendoza Alma Faviola et al, 2023, Annals of Human Biology CrossRef
27. Effect of ADME gene polymorphisms on pemetrexed pharmacokinetics in patients with non-small-cell lung cancer: A prospective study
    Sharath Kumar et al, 2022, Cancer Res Stat Treat CrossRef